AD	

Award Number: DAMD17-03-1-0429

TITLE: Proteomic Analysis to Identify Novel Circulating Breast

Cancer Markers

PRINCIPAL INVESTIGATOR: Francisco J. Esteva, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer

Center

Houston, Texas 77030

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Buddet. Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED		
(Leave blank)	June 2004	Annual (27 May	2003 - 26 May 2004)	
4. TITLE AND SUBTITLE Proteomic Analysis to Identify Novel Circulating Breast Cancer Markers			5. FUNDING NUMBERS DAMD17-03-1-0429	
6. AUTHOR(S)				
Francisco J. Esteva, M.D				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center			8. PERFORMING ORGANIZATION REPORT NUMBER	
Houston, Texas 77030				
E-Mail: festeva@mdanderso				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS	(ES)		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
U.S. Army Medical Resear Fort Detrick, Maryland		nd		
11. SUPPLEMENTARY NOTES				

#### 12a. DISTRIBUTION / AVAILABILITY STATEMENT

12b. DISTRIBUTION CODE

Approved for Public Release; Distribution Unlimited

#### 13. ABSTRACT (Maximum 200 Words)

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004. I am still waiting for the final approval of the protocol and informed consent. I was informed that I can't initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

14. SUBJECT TERMS Breast neoplasms, proteomics, serum, tumor markers biological			15. NUMBER OF PAGES 4
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

# **Table of Contents**

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	4
Reportable Outcomes	4
Conclusions	4
References	4
Appendices	

### Introduction

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

## Body

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004.

# Key Research Accomplishments

N/A

## Reportable Outcomes

 $\cdot N/A$ 

#### **Conclusions**

We are awaiting the final approval of the protocol and informed consent by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I was informed that I can't initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

### References

N/A